Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Sutro Biopharma, Inc. is a clinical-stage oncology company focused on developing site-specific and novel-format antibody drug conjugates (ADCs) [1][3] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 AM PT / 2:15 PM ET [1] Company Overview - Sutro Biopharma is advancing a next-generation ADC platform that aims to deliver single- and dual-payload ADCs for cancer treatment [3] - The company's technology optimizes the antibody, linker, and payload to enhance drug exposure, minimize side effects, and broaden the range of treatable tumor types [3] - Sutro's pipeline targets large oncology markets with limited treatment options, addressing significant needs for improved therapies [3]